AffyImmune Therapeutics, Inc.   Report issue

For profit Phase 1
Founded: Natick Massachusetts United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04420754
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

AffyImmune Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

aic100 car t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Thyroid Carcinoma, Anaplastic (Phase 1)

Thyroid Diseases (Phase 1)

Thyroid Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1